Consent Statement for PDE5 Inhibitor Use in Transgender Men
I recommend creating a comprehensive informed consent document that addresses the standard risks and contraindications of PDE5 inhibitors as outlined in FDA labeling, while acknowledging the limited evidence specific to transgender men. The consent should prioritize cardiovascular safety screening, drug interactions, and realistic expectations about efficacy.
Essential Components for the Consent Statement
Cardiovascular Risk Assessment
Before prescribing PDE5 inhibitors, you must stratify cardiovascular risk using the framework from the 2025 EAU guidelines 1:
- Low-risk patients (controlled hypertension, mild valvular disease, NYHA class I-II heart failure achieving 5 METs without ischemia) can generally use PDE5 inhibitors safely
- Intermediate-risk patients (mild-moderate stable angina, recent MI 2-8 weeks ago, NYHA class III heart failure) require exercise stress testing before approval
- High-risk patients (unstable angina, uncontrolled hypertension, NYHA class IV heart failure, recent MI <2 weeks, high-risk arrhythmias) should not receive PDE5 inhibitors
Absolute Contraindications to Include
The consent must explicitly state these contraindications from FDA labeling 2, 3:
- Concurrent nitrate use (nitroglycerin, isosorbide) or recreational "poppers" (amyl/butyl nitrite) - can cause life-threatening hypotension
- Guanylate cyclase stimulators (riociguat) use
- Known allergy to the specific PDE5 inhibitor
- Severe cardiovascular disease as defined above
Critical Drug Interactions
The consent should list medications requiring dose adjustment or caution 2:
- Alpha-blockers (terazosin, tamsulosin, doxazosin, alfuzosin) - risk of symptomatic hypotension
- HIV protease inhibitors (ritonavir)
- Antifungals (ketoconazole, itraconazole)
- Antibiotics (clarithromycin, erythromycin)
- Other antihypertensive medications
Medical Conditions Requiring Disclosure
Include these conditions from FDA labeling 2, 3:
- Retinitis pigmentosa or history of NAION (non-arteritic anterior ischemic optic neuropathy)
- Anatomical penile deformities (Peyronie's disease, angulation)
- Conditions predisposing to priapism (sickle cell anemia, multiple myeloma, leukemia)
- Bleeding disorders or active peptic ulcers
- Liver or kidney disease requiring dialysis
- History of stroke
Common Side Effects
List the most common adverse events 2, 4:
- Headache
- Indigestion/dyspepsia
- Back pain and muscle aches (typically 12-24 hours after dosing, resolving within 2 days)
- Flushing
- Nasal congestion
- Visual disturbances (blue-tinted vision, light sensitivity)
Serious Adverse Events Requiring Immediate Medical Attention
The consent must emphasize seeking emergency care for 2, 3:
- Priapism (erection lasting >4 hours) - can cause permanent erectile tissue damage
- Sudden vision loss in one or both eyes (possible NAION)
- Sudden hearing loss or decrease, possibly with tinnitus and dizziness
- Chest pain, dizziness, or nausea during sexual activity - stop activity immediately
Dosing and Usage Instructions
Include specific guidance from FDA labeling 2:
- As-needed dosing: Take 30 minutes to 1 hour before anticipated sexual activity (sildenafil/vardenafil) or up to 36 hours in advance (tadalafil)
- Daily dosing option: Lower-dose tadalafil taken at the same time daily
- Maximum frequency: Do not exceed one dose per 24 hours
- Sexual stimulation required: PDE5 inhibitors do not cause automatic erections
- Alcohol limitation: Avoid excessive alcohol (>5 drinks) which increases side effect risk
Transgender-Specific Considerations
While evidence is limited for transgender men specifically, the consent should address:
- Efficacy expectations: PDE5 inhibitors are FDA-approved for erectile dysfunction in cisgender men 5. Evidence in transgender men is limited, and response may vary based on genital anatomy, testosterone therapy duration, and surgical history
- Informed consent framework: Acknowledge that use in transgender men represents an area with emerging evidence 6, 7
- Realistic outcomes: Sexual stimulation is required; medication does not guarantee erection or orgasm
- Not a contraceptive: Does not prevent pregnancy or sexually transmitted infections
Documentation Requirements
The consent should include:
- Patient acknowledgment of reviewing all risks, benefits, and alternatives
- Confirmation that questions were answered
- Agreement to report adverse events promptly
- Understanding of proper dosing and contraindications
- Signature and date from both patient and prescriber
Key Pitfalls to Avoid
Do not prescribe without cardiovascular screening - sexual activity itself carries cardiac risk, and the 2025 EAU guidelines provide clear stratification criteria 1. This is non-negotiable.
Do not overlook nitrate use - this includes both prescribed medications and recreational drugs. The combination can be fatal 2.
Do not promise specific outcomes - PDE5 inhibitors improve erectile function in 60-70% of users, but 30% may not respond 8. Set realistic expectations to avoid dissatisfaction.
Do not ignore the informed consent process - research shows providers often perform perfunctory consent rather than true informed consent 6, 7. Take time to ensure genuine understanding, particularly regarding serious adverse events like priapism and vision loss.